Skip to main content
Clinical Trials/JPRN-UMIN000003830
JPRN-UMIN000003830
Completed
未知

Effect of pioglitazone and metformin in combination with insulin therapy in patients with type 2 diabetes - Effect of pioglitazone and metformin in combination with insulin therapy in patients with type 2 diabetes

Chigasaki Municipal Hospital0 sites250 target enrollmentJuly 1, 2010
ConditionsType 2 diabetes

Overview

Phase
未知
Intervention
Not specified
Conditions
Type 2 diabetes
Sponsor
Chigasaki Municipal Hospital
Enrollment
250
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 1, 2010
End Date
September 27, 2013
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with type 1 diabetes 2\) Patients receiving thiazolidiones or biguanides 3\) Heart failure defined as NYHA class III or above 4\) Having allergy to thiazolidiones or biguanides 5\) Patients with severe liver failure or renal failure 6\) History of acute coronary syndrome or cerebrovascular accident with in 3 months 7\) Pregnant or breastfeeding 8\) Patients with familial hypercholesterolemia 9\) Other patients determined to be inappropriate by physician

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Effects of a Pioglitazone/ Metformin Fixed Combination in Comparison to Metformin in Combination with Glimepiride on Diabetic DyslipidemiaPatients with Type 2 Diabetes mellitus (HbA1c > 6.5% and >/ = 9%) and diabetic dylipidemia inefficiently treated with Metformin monotherapy (maximal individually tolerated dose) will be eligible for this trial.MedDRA version: 8.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate control
EUCTR2006-004455-37-DETakeda Pharma GmbH260
Active, not recruiting
Not Applicable
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb Study
EUCTR2007-006706-14-ATTakeda Pharma GmbH200
Active, not recruiting
Not Applicable
Impact of Pioglitazone, Metformin and the combination of both on cardiovascular risk in insulin-treated patients with Type 2 diabetes – The PIOcomb Study - PIOcomb StudyDiabetes mellitus type 2MedDRA version: 9.1Level: LLTClassification code 10045242Term: Type II diabetes mellitus
EUCTR2007-006706-14-DETakeda Pharma GmbH
Completed
Not Applicable
Differential effects of metformin and pioglithazone on hs-CRP in patients with type II DM.diabetes mellitus II.non-insulin-dependent diabetes mellitus
IRCT201109067482N1Qazvin University of Medical Sciences40
Completed
Not Applicable
Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetestype 2 diabetes
JPRN-UMIN000001891Jikei University School of Medicine20